domingo, 28 de mayo de 2017

Epigenomics, Pharmacoepigenomics, and Personalized Medicine in Cervical Cancer. - PubMed - NCBI

Epigenomics, Pharmacoepigenomics, and Personalized Medicine in Cervical Cancer. - PubMed - NCBI



 2017 May 19. doi: 10.1159/000475804. [Epub ahead of print]

Epigenomics, Pharmacoepigenomics, and Personalized Medicine in Cervical Cancer.

Abstract

Epigenomics encompasses the study of genome-wide changes in DNA methylation, histone modifications and noncoding RNAs leading to altered transcription, chromatin structure, and posttranscription RNA processing, respectively, resulting in an altered rate of gene expression. The role of epigenetic modifications facilitating human diseases is well established. Previous studies have identified histone and cytosine code during normal and pathological conditions with special emphasis on how these modifications regulate transcriptional events. Recent studies have also mapped these epigenetic modification and pathways leading to carcinogenesis. Discovery of drugs that target proteins/enzymes in the epigenetic pathways may provide better therapeutic opportunities, and identification of such modulators for DNA methylation, histone modifications, and expression of noncoding RNAs for several cancer types is underway. In this review, we provide a detailed description of recent developments in the field of epigenetics and its impact on personalized medicine to manage cervical cancer.

KEYWORDS:

Cervical cancer; Epigenetics; Personalized medicine; Risk factors

PMID:
 
28521327
 
DOI:
 
10.1159/000475804
Free full text

No hay comentarios:

Publicar un comentario